What are the treatment options for patients with duodenal cancer who have progressed on FOLFIRINOX and what are the quality of evidence behind this?
Answer from: Medical Oncologist at Academic Institution
The quality of evidence for almost all treatments in small bowel adenocarcinomas is poor to some extent. First, I would look at the NGS data I am sure you have or can obtain easily for a molecular treatment if applicable (TMB > 10 = pembrolizumab, MSI-H = checkpoint inhibitor, NTRK = e.g. entrect...